DISC-3405 (novel agent for Polycythemia Vera)

Current understanding

To be populated as evidence accumulates.

2026-10-05 — A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera: cross-connection with ag-236: AG-236 joins DISC-3405 as another novel non-cytoreductive PV agent being evaluated for durable hematocrit control without phlebotomy. (novelty: 3)
2026-08-31 — FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo): cross-connection with rusfertide: Both are hepcidin-axis modulators competing in the PV space; rusfertide is now the first FDA-approved entrant in this class. (novelty: 4)
2026-06-01 — A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera: cross-connection with sapablursen-tmprss6-antisense: Both sapablursen and DISC-3405 are novel hepcidin/iron-axis modulators being developed for PV as alternatives to phlebotomy and cytoreduction, representing a converging therapeutic strategy. (novelty: 4)
2026-03-04 — A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV): Phase 2 open-label, multicenter, within-participant dose-escalation study (up to 2 dose levels) launched to evaluate safety, tolerability, efficacy, PK, and PD of DISC-3405 in patients with polycythemia vera (trial-early). (novelty: 4)